ArticleScientific reports2025
The pattern change of hepatitis B virus genetic diversity in Northwestern Tanzania.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Cytokine gene polymorphisms and susceptibility to chronic hepatitis B virus infection in familial clusters from Iran: a cross-sectional study.BMC infectious diseases · 2026Article
- mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress.Molecular therapy. Nucleic acids · 2026Review
- Sero-Molecular Markers and Genetic Diversity of Hepatitis B Virus Isolated From Hemodialysis Patients From Jenin District, West Bank, Palestine.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- HBV genotype distribution and S gene mutations in HIV-HBV co-infected patients: insights from North India.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus genetic diversity (HBV) evaluation is scarcely done in Tanzania, imposing a crucial knowledge gap toward elimination of HBV infection by 2030. This cross-sectional study was conducted on purposively selected 21 plasma samples with high HBV-deoxyribonucleic acid (DNA) levels of > 300,000IU/mL. DNA extraction was done using Qiagen DNA Blood Mini Kit (Qiagen, Hilden, Germany). Partial amplification of 423 bp of pol gene, sequencing and analysis; and statistical analysis by STATA version 15 were done. These patients had mean age of 41 ± 11 years with HBV-DNA median of 979 [185.5-8457.5] IU/mL. The genotypes detected were HBV/A; 76.2% (16/21), HBV/D; 19% (4/21), and lastly HBV/G; 4.8% (1/21). Most of the HBV/As and all of the HBV/Ds identified in this study did not cluster with HBV/As and HBV/Ds from other parts of the world. Overall, 19% (4/21) of the patients had HBV escape mutations (T123V, Y134N, P120T and T123A). In conclusion, HBV/A and HBV/D are predominant over time in North-western Tanzania. Most HBV/A and all HBV/D are unique to Tanzania as had been previously reported. However, the pattern of hepatitis B virus genetic diversity is changing in Northwestern Tanzania with occurrence of HBV/G as new genotype in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.